Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
New Horizon Health HK$781.7 million top-up placement of shares
We advised New Horizon Health on the top-up placement
Jinxin Fertility Group HK$1.17 billion top-up placement of shares
The shares are listed on the Hong Kong Stock Exchange
Novavax $175.25 million convertible senior notes offering
The 5% convertible notes are due 2027
Terns Pharmaceuticals $86 million stock offering
The stock is listed on the Nasdaq Global Select Market
Coherus BioSciences $150 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Priveterra Acquisition initial business combination with AEON Biopharma
We are advising Priveterra on the transaction
Illumina $1 billion notes offering
The investment-grade notes are due 2027
Prometheus Biosciences $500 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Lantheus Holdings $575 million convertible senior notes offering
The 2.625% convertible notes are due 2027